Investors Purchase Large Volume of MannKind Call Options (NASDAQ:MNKD)

MannKind Corporation (NASDAQ:MNKD) was the recipient of some unusual options trading activity on Wednesday. Traders acquired 3,175 call options on the stock. This is an increase of 140% compared to the average daily volume of 1,324 call options.

MannKind Price Performance

Shares of MannKind stock opened at $3.24 on Friday. The firm’s fifty day simple moving average is $5.61 and its 200-day simple moving average is $5.35. MannKind has a 12 month low of $2.93 and a 12 month high of $6.51. The stock has a market capitalization of $994.91 million, a price-to-earnings ratio of 32.40 and a beta of 0.84.

MannKind (NASDAQ:MNKD) last released its earnings results on Thursday, February 26th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by ($0.04). MannKind had a negative return on equity of 49.33% and a net margin of 9.32%.The business had revenue of $111.96 million for the quarter, compared to analyst estimates of $99.85 million. During the same quarter in the previous year, the firm posted $0.03 EPS. The business’s revenue for the quarter was up 45.8% on a year-over-year basis. Analysts anticipate that MannKind will post 0.1 earnings per share for the current year.

Insider Buying and Selling at MannKind

In other MannKind news, insider Stuart A. Tross sold 47,006 shares of the company’s stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $6.33, for a total value of $297,547.98. Following the completion of the transaction, the insider owned 985,007 shares in the company, valued at approximately $6,235,094.31. This represents a 4.55% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Michael Castagna sold 107,920 shares of the firm’s stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $5.57, for a total value of $601,114.40. Following the sale, the chief executive officer owned 2,504,792 shares in the company, valued at $13,951,691.44. This trade represents a 4.13% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders sold 262,846 shares of company stock valued at $1,546,840. Company insiders own 2.70% of the company’s stock.

Institutional Trading of MannKind

Institutional investors have recently added to or reduced their stakes in the stock. Quaker Wealth Management LLC increased its holdings in MannKind by 200.0% in the second quarter. Quaker Wealth Management LLC now owns 7,000 shares of the biopharmaceutical company’s stock valued at $26,000 after buying an additional 14,000 shares in the last quarter. Caitong International Asset Management Co. Ltd increased its stake in MannKind by 108.0% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 5,636 shares of the biopharmaceutical company’s stock valued at $32,000 after purchasing an additional 2,927 shares in the last quarter. Sumitomo Mitsui Trust Group Inc. acquired a new position in MannKind during the second quarter worth $42,000. International Assets Investment Management LLC purchased a new stake in MannKind during the fourth quarter worth $45,000. Finally, Burkett Financial Services LLC purchased a new stake in MannKind during the fourth quarter worth $59,000. Hedge funds and other institutional investors own 49.55% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on MNKD shares. Leerink Partners started coverage on shares of MannKind in a report on Thursday, November 13th. They issued an “outperform” rating and a $7.00 target price for the company. Weiss Ratings reaffirmed a “hold (c)” rating on shares of MannKind in a research note on Thursday, January 22nd. Zacks Research lowered MannKind from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, February 10th. Wells Fargo & Company lowered their target price on MannKind from $10.00 to $8.00 and set an “overweight” rating for the company in a report on Tuesday, November 11th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of MannKind in a research report on Wednesday. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $9.93.

Key Headlines Impacting MannKind

Here are the key news stories impacting MannKind this week:

• Positive Sentiment: Revenue and commercial momentum — Q4 revenue came in ~$112M, up ~46% year-over-year, with Furoscix net sales up ~91% and management outlining a ~$450M 2026 revenue run‑rate plus Afrezza pediatric launch plans as upcoming catalysts. Company Press Release Run‑rate / Afrezza article
• Positive Sentiment: Analyst support — HC Wainwright reaffirmed a Buy rating and an $11 price target, signaling upside potential for some investors. Analyst note
• Positive Sentiment: Bullish options activity — unusually large call buying was reported ahead of results, which can reflect institutional/speculative interest in upside. (No direct article link available.)
• Neutral Sentiment: Earnings call materials available — full Q4 2025 earnings call transcript and slide deck were published for investors to review management’s commentary and guidance. Earnings transcript
• Negative Sentiment: EPS miss / unexpected loss — MannKind reported a ($0.05) EPS vs. the consensus loss of ($0.01), an earnings miss that drove immediate downside despite the revenue beat. Why stock tumbled MarketWatch coverage
• Negative Sentiment: Market reaction and technicals — the Q4 miss pushed the shares to a 52‑week low and triggered heavy selling / elevated volume. 52‑week low report
• Negative Sentiment: Competitive risk — separate industry news that United Therapeutics is considering a new treprostinil formulation added pressure on related small‑cap biotech names, which may have weighed on sentiment. Competitive risk article

About MannKind

MannKind Corporation is a biopharmaceutical company specialized in the development and commercialization of inhaled therapeutic products. The company’s core business revolves around its proprietary Technosphere® drug‐delivery platform, which is designed to enable rapid absorption of small‐molecule drugs through pulmonary administration. MannKind’s lead product, Afrezza®, is an inhaled insulin therapy intended for adults with type 1 and type 2 diabetes, offering users a rapid‐acting alternative to traditional injectable insulins.

Afrezza received U.S.